Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Assiut, Egypt.
Protein Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab, Alexandria 21934, Egypt; Pharmaceutical and Fermentation Industries Development Centre (PFIDC), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab, Alexandria, Egypt; Pharos University in Alexandria, Canal El Mahmoudia Street, Beside Green Plaza Complex, 21648, Alexandria, Egypt.
Int J Biol Macromol. 2024 Oct;277(Pt 4):134535. doi: 10.1016/j.ijbiomac.2024.134535. Epub 2024 Aug 5.
Microbial enzymes are crucial catalysts in various industries due to their versatility and efficiency. The microbial enzymes market has recently expanded due to increased demand for many reasons. Among them are eco-friendly solutions, developing novel microbial strains with enhanced enzymes that perform under harsh conditions, providing sustainability, and raising awareness about the benefits of enzyme-based products. By 2030, the global enzyme market is expected to account for $525 billion, with a growth rate of 6.7 %. L-asparaginase and L-glutaminase are among the leading applied microbial enzymes in antitumor therapy, with a growing market share of 16.5 % and 9.5 %, respectively. The use of microbial enzymes has opened new opportunities to fight various tumors, including leukemia, lymphosarcoma, and breast cancer, which has increased their demand in the pharmaceutical and medicine sectors. Despite their promising applications, commercial use of microbial enzymes faces challenges such as short half-life, immunogenicity, toxicity, and other side effects. Therefore, this review explores the industrial production, purification, formulation, and commercial utilization of microbial enzymes, along with an overview of the global enzyme market. With ongoing discoveries of novel enzymes and their applications, enzyme technology offers promising avenues for cancer treatment and other therapeutic interventions.
微生物酶因其多功能性和高效性而成为各个行业的关键催化剂。由于多种原因，微生物酶市场最近有所扩大。其中包括环保解决方案、开发在恶劣条件下表现更出色的新型微生物菌株以提供可持续性，以及提高对基于酶产品的益处的认识。到 2030 年，全球酶市场预计将达到 5250 亿美元，增长率为 6.7%。L-天冬酰胺酶和 L-谷氨酰胺酶是抗肿瘤治疗中应用最广泛的微生物酶之一，其市场份额分别增长了 16.5%和 9.5%。微生物酶的使用为治疗各种肿瘤（包括白血病、淋巴肉瘤和乳腺癌）开辟了新的机会，这增加了它们在制药和医药领域的需求。尽管它们有广泛的应用前景，但微生物酶的商业应用面临半衰期短、免疫原性、毒性和其他副作用等挑战。因此，本综述探讨了微生物酶的工业生产、纯化、配方和商业利用，以及全球酶市场的概述。随着新型酶及其应用的不断发现，酶技术为癌症治疗和其他治疗干预提供了有前途的途径。
